TG Therapeutics (TGTX) to Release Quarterly Earnings on Monday

Key Points

• TG Therapeutics is set to announce its Q2 2025 earnings on August 5th, with analysts projecting earnings of $0.27 per share and revenue of $147.76 million.
• In its last earnings report, TG Therapeutics missed expectations, reporting only $0.03 earnings per share on revenue of $120.86 million for Q1 2025.
• The stock currently has a market cap of $5.71 billion and analysts have given it a consensus rating of "Moderate Buy" with an average price target of $43.80.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Monday, August 4th. Analysts expect TG Therapeutics to post earnings of $0.27 per share and revenue of $147.76 million for the quarter.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The business had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The company's quarterly revenue was up 90.4% on a year-over-year basis. During the same period last year, the firm earned ($0.07) earnings per share. On average, analysts expect TG Therapeutics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

TG Therapeutics Trading Down 2.1%

TGTX stock traded down $0.77 during midday trading on Thursday, reaching $35.50. 1,811,501 shares of the company's stock traded hands, compared to its average volume of 1,456,212. The business has a 50-day moving average price of $36.82 and a two-hundred day moving average price of $35.98. TG Therapeutics has a fifty-two week low of $16.65 and a fifty-two week high of $46.48. The company has a debt-to-equity ratio of 1.03, a current ratio of 4.02 and a quick ratio of 3.04. The company has a market capitalization of $5.64 billion, a P/E ratio of 147.92 and a beta of 1.91.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group raised shares of TG Therapeutics to a "hold" rating and set a $37.00 price target on the stock in a report on Thursday, July 10th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, TG Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $43.80.

Insiders Place Their Bets

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the company's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the transaction, the director directly owned 228,816 shares of the company's stock, valued at $8,452,463.04. This represents a 4.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 10.64% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds have recently made changes to their positions in TGTX. Royal Bank of Canada boosted its position in shares of TG Therapeutics by 16.4% during the first quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company's stock valued at $2,985,000 after buying an additional 10,660 shares during the last quarter. NewEdge Advisors LLC increased its position in shares of TG Therapeutics by 9.6% during the 1st quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company's stock valued at $299,000 after purchasing an additional 665 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in TG Therapeutics by 21.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company's stock worth $75,683,000 after buying an additional 345,059 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in TG Therapeutics by 5.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company's stock valued at $11,319,000 after buying an additional 14,689 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.